207 related articles for article (PubMed ID: 14613031)
1. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).
Allen LF; Sebolt-Leopold J; Meyer MB
Semin Oncol; 2003 Oct; 30(5 Suppl 16):105-16. PubMed ID: 14613031
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
3. Development of anticancer drugs targeting the MAP kinase pathway.
Sebolt-Leopold JS
Oncogene; 2000 Dec; 19(56):6594-9. PubMed ID: 11426644
[TBL] [Abstract][Full Text] [Related]
4. Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models.
Watanabe K; Tanimura S; Uchiyama A; Sakamoto T; Kawabata T; Ozaki K; Kohno M
Clin Cancer Res; 2010 Feb; 16(4):1170-8. PubMed ID: 20145173
[TBL] [Abstract][Full Text] [Related]
5. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
6. Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism.
Romerio F; Riva A; Zella D
Br J Cancer; 2000 Aug; 83(4):532-8. PubMed ID: 10945503
[TBL] [Abstract][Full Text] [Related]
7. MEK inhibition enhances bleomycin A5-induced apoptosis in an oral cancer cell line: signaling mechanisms and therapeutic opportunities.
Yang LC; Yang SH; Tai KW; Chou MY; Yang JJ
J Oral Pathol Med; 2004 Jan; 33(1):37-45. PubMed ID: 14675139
[TBL] [Abstract][Full Text] [Related]
8. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
9. The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines.
Mattingly RR; Kraniak JM; Dilworth JT; Mathieu P; Bealmear B; Nowak JE; Benjamins JA; Tainsky MA; Reiners JJ
J Pharmacol Exp Ther; 2006 Jan; 316(1):456-65. PubMed ID: 16239399
[TBL] [Abstract][Full Text] [Related]
10. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
Yang R; Piperdi S; Gorlick R
Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
[TBL] [Abstract][Full Text] [Related]
11. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.
Miranda MB; McGuire TF; Johnson DE
Leukemia; 2002 Apr; 16(4):683-92. PubMed ID: 11960350
[TBL] [Abstract][Full Text] [Related]
12. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
13. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the MEK/ERK signaling pathway blocks a subset of B cell responses to antigen.
Richards JD; Davé SH; Chou CH; Mamchak AA; DeFranco AL
J Immunol; 2001 Mar; 166(6):3855-64. PubMed ID: 11238629
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
McCubrey JA; Milella M; Tafuri A; Martelli AM; Lunghi P; Bonati A; Cervello M; Lee JT; Steelman LS
Curr Opin Investig Drugs; 2008 Jun; 9(6):614-30. PubMed ID: 18516761
[TBL] [Abstract][Full Text] [Related]
16. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
Friday BB; Adjei AA
Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
[TBL] [Abstract][Full Text] [Related]
17. cAMP inhibits the proliferation of retinal pigmented epithelial cells through the inhibition of ERK1/2 in a PKA-independent manner.
Hecquet C; Lefevre G; Valtink M; Engelmann K; Mascarelli F
Oncogene; 2002 Sep; 21(39):6101-12. PubMed ID: 12203122
[TBL] [Abstract][Full Text] [Related]
18. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.
Blalock WL; Navolanic PM; Steelman LS; Shelton JG; Moye PW; Lee JT; Franklin RA; Mirza A; McMahon M; White MK; McCubrey JA
Leukemia; 2003 Jun; 17(6):1058-67. PubMed ID: 12764369
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
Ripple MO; Kalmadi S; Eastman A
Breast Cancer Res Treat; 2005 Sep; 93(2):177-88. PubMed ID: 16187238
[TBL] [Abstract][Full Text] [Related]
20. Activation of phosphatidylinositol 3-kinase and extracellular signal-regulated kinase is required for glial cell line-derived neurotrophic factor-induced migration and invasion of pancreatic carcinoma cells.
Veit C; Genze F; Menke A; Hoeffert S; Gress TM; Gierschik P; Giehl K
Cancer Res; 2004 Aug; 64(15):5291-300. PubMed ID: 15289335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
